| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
Sprout Growth II, L.P.
|
Financial |
5
|
1 |
This document is a confidential financial schedule detailing the 'Healthcare Technology Portfolio' performance for two funds: Sprout Capital VII, L.P. and Sprout Growth II, L.P., as of March 31, 2014. It lists specific portfolio companies (such as WebMD, Cephalon, and Adeza Biomedical), the vintage year of investment (ranging 1994-2003), investment costs, realized values, and Internal Rates of Return (IRR). The document bears a House Oversight Bates stamp (HOUSE_OVERSIGHT_024104), indicating it was part of a congressional investigation, likely related to financial probes involving entities connected to the broader Epstein investigation.
This document is a financial appendix page (marked CONFIDENTIAL) bearing a House Oversight Bates stamp (HOUSE_OVERSIGHT_024103). It details the investment performance of 'Sprout Capital VIII, L.P. (Healthcare Technology Portfolio)' as of March 31, 2014. It lists specific investments in healthcare and technology companies (such as Charles River Laboratories and eHealth, Inc.), showing the vintage year (ranging from 1998-2000), total cost, realized value, and internal rate of return (IRR) for each.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity